Drug search by name

Peginterferon alfa-2a Subcutaneous and Renal dysfunction

Result of checking the interaction of drug Peginterferon alfa-2a Subcutaneous and disease Renal dysfunction for safety when used together.

Check result:

Peginterferon alfa-2a Subcutaneous <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).

References:

"Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
"Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.

Peginterferon alfa-2a Subcutaneous

Generic Name: peginterferon alfa-2a

Brand Name: Pegasys, Pegasys ProClick Autoinjector, Pegasys Prefilled Syringe

Synonyms: Peginterferon alfa-2a, Peginterferon Alfa-2a

What is Peginterferon alfa-2a Subcutaneous?